AbbVie has agreed to acquire Apogee Therapeutics for approximately $10.9 billion, expanding its immunology pipeline and respiratory disease portfolio. The transaction is expected to close in the third quarter of 2026.
Under the terms of the agreement, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash, according to a June 22 company news release. The boards of directors of both companies unanimously approved the transaction.
The acquisition adds several clinical-stage assets focused on inflammatory and immunological diseases, including Apogee’s lead candidate, zumilokibart (APG777), a monoclonal antibody targeting IL-13 that is being developed for patients with atopic dermatitis.
Apogee’s pipeline also includes APG273, a combination therapy targeting IL-13 and thymic stromal lymphopoietin that is being developed for asthma. In a phase 2 trial, approximately two-thirds of patients receiving zumilokibart achieved significant skin clearance at 16 weeks.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
